The new scoring system for evaluation of skin inflammation extent and severity in patients with atopic dermatitis
- PMID: 16356394
The new scoring system for evaluation of skin inflammation extent and severity in patients with atopic dermatitis
Abstract
The new scoring system for assessment of the extent and severity of skin inflammation index in atopic dermatitis patients, W-AZS, is presented. The system provides detailed assessment of both subjective and objective signs and symptoms of atopic dermatitis. With the use of W-AZS, acute and chronic skin manifestations of inflammatory process are appropriately evaluated and scored. It also enables the practitioner to assess various localizations of skin lesions at different time points. W-AZS is a relatively easy and rapid index to perform, and it seems very beneficial for clinicians. Other scoring systems used in atopic dermatitis are also presented, analyzed and compared, e.g., Atopic Dermatitis Area and Severity Index (ADASI), SCORing Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), Six Area, Six Sign Atopic Dermatitis (SASSAD), and Three-Item Severity score (TIS). There is a strong necessity to standardize clinical evaluation of the extent and severity of skin diseases such as atopic dermatitis, as laboratory techniques and parameters are not really of great use for practitioners.
Similar articles
-
Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score.Br J Dermatol. 2007 Oct;157(4):645-8. doi: 10.1111/j.1365-2133.2007.08112.x. Epub 2007 Aug 21. Br J Dermatol. 2007. PMID: 17714568 Review.
-
The value of SCORAD and beyond. Towards a standardized evaluation of severity?Allergy. 2004 Aug;59 Suppl 78:61-5. doi: 10.1111/j.1398-9995.2004.00651.x. Allergy. 2004. PMID: 15245360
-
The objective severity assessment of atopic dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitis.Br J Dermatol. 2005 Oct;153(4):767-73. doi: 10.1111/j.1365-2133.2005.06697.x. Br J Dermatol. 2005. PMID: 16181458
-
The Self-administered Eczema Area and Severity Index in children with moderate to severe atopic dermatitis: better estimation of AD body surface area than severity.Pediatr Dermatol. 2010 Sep-Oct;27(5):470-5. doi: 10.1111/j.1525-1470.2010.01285.x. Epub 2010 Aug 26. Pediatr Dermatol. 2010. PMID: 20796235
-
Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.J Allergy Clin Immunol. 2013 Dec;132(6):1337-47. doi: 10.1016/j.jaci.2013.07.008. Epub 2013 Sep 12. J Allergy Clin Immunol. 2013. PMID: 24035157 Review.
Cited by
-
Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review.J Invest Dermatol. 2022 Feb;142(2):364-381. doi: 10.1016/j.jid.2021.06.033. Epub 2021 Aug 2. J Invest Dermatol. 2022. PMID: 34352262 Free PMC article.
-
Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations.Postepy Dermatol Alergol. 2015 Dec;32(6):426-30. doi: 10.5114/pdia.2015.56097. Epub 2015 Dec 11. Postepy Dermatol Alergol. 2015. PMID: 26755905 Free PMC article.
-
TRPA1 and CGRP antagonists counteract vesicant-induced skin injury and inflammation.Toxicol Lett. 2018 Sep 1;293:140-148. doi: 10.1016/j.toxlet.2018.03.007. Epub 2018 Mar 10. Toxicol Lett. 2018. PMID: 29535050 Free PMC article.
-
Pharmacologic Inhibition of Transient Receptor Potential Ion Channel Ankyrin 1 Counteracts 2-Chlorobenzalmalononitrile Tear Gas Agent-Induced Cutaneous Injuries.J Pharmacol Exp Ther. 2024 Jan 17;388(2):613-623. doi: 10.1124/jpet.123.001666. J Pharmacol Exp Ther. 2024. PMID: 38050077 Free PMC article.
-
Treatment of eczema.Clin Rev Allergy Immunol. 2007 Dec;33(3):204-25. doi: 10.1007/s12016-007-0033-8. Clin Rev Allergy Immunol. 2007. PMID: 18163227 Review.